• 3Q23 Daxxify sales were $22.0M, -3% QoQ. (There is no meaningful YoY growth figure because Daxxify was not yet on the market during 3Q22.) Note: The slight QoQ decline during the seasonally slow third calendar quarter is effectively an increase in the projected annualized rate.
• 3Q23 dermal-filler sales were $32.1M, +1% QoQ and +23% YoY.
• 3Q23 non-GAAP operating expenses (excluding revenue and COGS) were $69.0. (RVNC’s guidance for full-year 2023 non-GAAP operating expenses is $315-335M.)
• Cash at 9/30/23 was $300.2M, a $19.5M decrease relative to 6/30/23. (RVNC raised $50M in Aug 2023 from the third tranche of the Athyrium Capital loan.)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.